Financial Ratios Arecor Therapeutics plc
Equities
AREC
GB00BMWLM973
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 66.00 GBX | 0.00% |
|
0.00% | -18.01% |
| Apr. 20 | Arecor Therapeutics plc, 2025 Earnings Call, Apr 13, 2026 | |
| Apr. 13 | Arecor Therapeutics swings to annual profit; hails insulin product | AN |
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
Profitability | |||||||
Return on Assets | -49.89 | -29.64 | -30.63 | -30.88 | -38.43 | ||
Return on Total Capital | -69.84 | -34.67 | -35.8 | -41.54 | -59.96 | ||
Return On Equity % | -138.25 | -63.85 | -51.44 | -63.41 | -137.62 | ||
Return on Common Equity | -138.25 | -63.85 | -51.44 | -63.41 | -137.62 | ||
Margin Analysis | |||||||
Gross Profit Margin % | 100 | 100 | 100 | 100 | 30.54 | ||
SG&A Margin | 96.7 | 206.3 | 223.93 | 194.9 | 122.26 | ||
EBITDA Margin % | -196.75 | -509.59 | -426.97 | -194.18 | -140.47 | ||
EBITA Margin % | -201.44 | -515.46 | -431.46 | -198.51 | -144.07 | ||
EBIT Margin % | -201.93 | -516.15 | -435.25 | -200.63 | -146.63 | ||
Income From Continuing Operations Margin % | -162.13 | -532.73 | -385.35 | -187.05 | -202.57 | ||
Net Income Margin % | -162.13 | -532.73 | -385.35 | -187.05 | -202.57 | ||
Net Avail. For Common Margin % | -162.13 | -532.73 | -385.35 | -187.05 | -202.57 | ||
Normalized Net Income Margin | -129.31 | -323.73 | -269.74 | -121.65 | -90.66 | ||
Levered Free Cash Flow Margin | -87.04 | -310.91 | -297.18 | -65.62 | -129.02 | ||
Unlevered Free Cash Flow Margin | -84.02 | -309.73 | -296.5 | -65.41 | -128.75 | ||
Asset Turnover | |||||||
Asset Turnover | 0.4 | 0.09 | 0.11 | 0.25 | 0.42 | ||
Fixed Assets Turnover | 5.06 | 3.29 | 4.12 | 5.47 | 8.19 | ||
Receivables Turnover (Average Receivables) | 5.9 | 2.93 | 1.64 | 3.12 | 2.11 | ||
Inventory Turnover (Average Inventory) | - | - | - | - | 5.62 | ||
Short Term Liquidity | |||||||
Current Ratio | 2.71 | 9.05 | 4.69 | 2.17 | 2.53 | ||
Quick Ratio | 2.67 | 8.77 | 4.38 | 1.96 | 2.08 | ||
Operating Cash Flow to Current Liabilities | -1.32 | -2.4 | -2.89 | -1.13 | -2.81 | ||
Days Sales Outstanding (Average Receivables) | 62.05 | 124.5 | 222.3 | 117.01 | 173.8 | ||
Days Outstanding Inventory (Average Inventory) | - | - | - | - | 65.12 | ||
Average Days Payable Outstanding | - | - | - | - | 185.96 | ||
Cash Conversion Cycle (Average Days) | - | - | - | - | 52.96 | ||
Long Term Solvency | |||||||
Total Debt/Equity | 257.87 | 1.25 | 1.65 | 3.55 | 4.34 | ||
Total Debt / Total Capital | 72.06 | 1.23 | 1.62 | 3.43 | 4.16 | ||
LT Debt/Equity | 244.27 | 0.57 | 0.49 | 2.31 | 2.08 | ||
Long-Term Debt / Total Capital | 68.26 | 0.56 | 0.48 | 2.23 | 1.99 | ||
Total Liabilities / Total Assets | 81.94 | 11.34 | 19.8 | 38.04 | 38.67 | ||
EBIT / Interest Expense | -41.81 | -271.68 | -402.27 | -611.67 | -336.77 | ||
EBITDA / Interest Expense | -39.75 | -263.91 | -389.23 | -579.2 | -316.95 | ||
(EBITDA - Capex) / Interest Expense | -40.39 | -267.05 | -400.73 | -589.27 | -318 | ||
Total Debt / EBITDA | -0.61 | -0.04 | -0.03 | -0.04 | -0.03 | ||
Net Debt / EBITDA | 0.28 | 3.11 | 1.24 | 0.74 | 0.43 | ||
Total Debt / (EBITDA - Capex) | -0.6 | -0.04 | -0.03 | -0.04 | -0.03 | ||
Net Debt / (EBITDA - Capex) | 0.27 | 3.08 | 1.2 | 0.73 | 0.43 | ||
Growth Over Prior Year | |||||||
Total Revenues, 1 Yr. Growth % | -10.23 | -31.8 | 107.51 | 90.3 | 10.5 | ||
Gross Profit, 1 Yr. Growth % | -10.23 | -31.8 | 107.51 | 90.3 | 23.34 | ||
EBITDA, 1 Yr. Growth % | 27.93 | 76.68 | 73.87 | -12.44 | -20.07 | ||
EBITA, 1 Yr. Growth % | 27.61 | 74.53 | 73.7 | -11.43 | -19.81 | ||
EBIT, 1 Yr. Growth % | 27.52 | 74.36 | 74.99 | -11.28 | -19.25 | ||
Earnings From Cont. Operations, 1 Yr. Growth % | 25.71 | 124.16 | 50.11 | -7.62 | 19.66 | ||
Net Income, 1 Yr. Growth % | 25.71 | 124.16 | 50.11 | -7.62 | 19.66 | ||
Normalized Net Income, 1 Yr. Growth % | 30.48 | 70.79 | 72.91 | -13.19 | -17.65 | ||
Diluted EPS Before Extra, 1 Yr. Growth % | 22 | 58.12 | 19.49 | -12.71 | 9.58 | ||
Accounts Receivable, 1 Yr. Growth % | -84.25 | 812.82 | 211.1 | 241.57 | 11.6 | ||
Inventory, 1 Yr. Growth % | - | - | - | -31.83 | -38 | ||
Net Property, Plant and Equip., 1 Yr. Growth % | 27.18 | -12.77 | 155.49 | -0.48 | -52.04 | ||
Total Assets, 1 Yr. Growth % | -0.51 | 388.35 | 4.03 | -29.35 | -43.28 | ||
Tangible Book Value, 1 Yr. Growth % | -76.73 | 2.42K | -24.12 | -55.66 | -14.68 | ||
Common Equity, 1 Yr. Growth % | -75.88 | 2.3K | -5.9 | -45.42 | -43.85 | ||
Cash From Operations, 1 Yr. Growth % | 304.67 | 193.48 | 97.8 | -45.82 | 56.74 | ||
Capital Expenditures, 1 Yr. Growth % | 61.91 | 32.69 | 333.33 | -49.5 | -84.77 | ||
Levered Free Cash Flow, 1 Yr. Growth % | - | 143.59 | 98.34 | -57.52 | 117.19 | ||
Unlevered Free Cash Flow, 1 Yr. Growth % | - | 151.37 | 98.65 | -57.58 | 117.41 | ||
Compound Annual Growth Rate Over Two Years | |||||||
Total Revenues, 2 Yr. CAGR % | - | -21.75 | 18.96 | 98.72 | 45.01 | ||
Gross Profit, 2 Yr. CAGR % | - | -21.75 | 18.96 | 98.72 | -19.87 | ||
EBITDA, 2 Yr. CAGR % | - | 50.34 | 75.27 | 22.67 | -16.34 | ||
EBITA, 2 Yr. CAGR % | - | 49.24 | 74.11 | 23.32 | -15.72 | ||
EBIT, 2 Yr. CAGR % | - | 49.11 | 74.67 | 23.9 | -15.36 | ||
Earnings From Cont. Operations, 2 Yr. CAGR % | - | 67.85 | 83.43 | 17.75 | 5.14 | ||
Net Income, 2 Yr. CAGR % | - | 67.85 | 83.43 | 17.75 | 5.14 | ||
Normalized Net Income, 2 Yr. CAGR % | - | 49.27 | 71.84 | 21.82 | -15.45 | ||
Diluted EPS Before Extra, 2 Yr. CAGR % | - | 38.88 | 37.45 | 2.13 | -2.2 | ||
Accounts Receivable, 2 Yr. CAGR % | - | 19.66 | 432.89 | 78.48 | 95.24 | ||
Inventory, 2 Yr. CAGR % | - | - | - | - | -34.99 | ||
Net Property, Plant and Equip., 2 Yr. CAGR % | - | 5.42 | 49.29 | 59.46 | -30.91 | ||
Total Assets, 2 Yr. CAGR % | - | 120.43 | 125.4 | -14.27 | -36.7 | ||
Tangible Book Value, 2 Yr. CAGR % | - | 142.03 | 336.96 | -41.99 | -38.5 | ||
Common Equity, 2 Yr. CAGR % | - | 140.46 | 374.89 | -28.33 | -44.64 | ||
Cash From Operations, 2 Yr. CAGR % | - | 244.66 | 140.94 | 3.52 | -7.84 | ||
Capital Expenditures, 2 Yr. CAGR % | - | 46.16 | 139.79 | 47.93 | -72.26 | ||
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | 119.81 | -8.71 | -3.93 | ||
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | 123.46 | -8.67 | -3.95 | ||
Compound Annual Growth Rate Over Three Years | |||||||
Total Revenues, 3 Yr. CAGR % | - | - | 8.31 | 39.13 | 63.41 | ||
Gross Profit, 3 Yr. CAGR % | - | - | 8.31 | 39.13 | 10.04 | ||
EBITDA, 3 Yr. CAGR % | - | - | 57.8 | 38.53 | 6.35 | ||
EBITA, 3 Yr. CAGR % | - | - | 56.99 | 38.46 | 6.84 | ||
EBIT, 3 Yr. CAGR % | - | - | 57.28 | 38.84 | 7.42 | ||
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | 61.72 | 45.94 | 18.39 | ||
Net Income, 3 Yr. CAGR % | - | - | 61.72 | 45.94 | 18.39 | ||
Normalized Net Income, 3 Yr. CAGR % | - | - | 56.77 | 36.34 | 6.91 | ||
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | 32.09 | 18.15 | 4.55 | ||
Accounts Receivable, 3 Yr. CAGR % | - | - | 64.54 | 207.5 | 52.62 | ||
Net Property, Plant and Equip., 3 Yr. CAGR % | - | - | 41.61 | 30.41 | 6.84 | ||
Total Assets, 3 Yr. CAGR % | - | - | 71.62 | 53.11 | -25.3 | ||
Tangible Book Value, 3 Yr. CAGR % | - | - | 64.42 | 103.81 | -34.03 | ||
Common Equity, 3 Yr. CAGR % | - | - | 75.89 | 130.89 | -33.93 | ||
Cash From Operations, 3 Yr. CAGR % | - | - | 186.42 | 46.52 | 18.87 | ||
Capital Expenditures, 3 Yr. CAGR % | - | - | 109.97 | 42.67 | -30.66 | ||
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | - | 26.62 | 21.89 | ||
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | - | 27.99 | 21.96 | ||
Compound Annual Growth Rate Over Five Years | |||||||
Total Revenues, 5 Yr. CAGR % | - | - | - | - | 21.72 | ||
Gross Profit, 5 Yr. CAGR % | - | - | - | - | -3.99 | ||
EBITDA, 5 Yr. CAGR % | - | - | - | - | 22.14 | ||
EBITA, 5 Yr. CAGR % | - | - | - | - | 22.13 | ||
EBIT, 5 Yr. CAGR % | - | - | - | - | 22.48 | ||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | - | - | 36.13 | ||
Net Income, 5 Yr. CAGR % | - | - | - | - | 36.13 | ||
Normalized Net Income, 5 Yr. CAGR % | - | - | - | - | 22.18 | ||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | - | - | 17.13 | ||
Accounts Receivable, 5 Yr. CAGR % | - | - | - | - | 38.47 | ||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | - | - | 6.27 | ||
Total Assets, 5 Yr. CAGR % | - | - | - | - | 15.16 | ||
Tangible Book Value, 5 Yr. CAGR % | - | - | - | - | 10.95 | ||
Common Equity, 5 Yr. CAGR % | - | - | - | - | 10.77 | ||
Cash From Operations, 5 Yr. CAGR % | - | - | - | - | 81.97 | ||
Capital Expenditures, 5 Yr. CAGR % | - | - | - | - | -6.57 |
- Stock Market
- Equities
- AREC Stock
- Financials Arecor Therapeutics plc
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















